Tumor markers of breast cancer: New prospectives

Kabel, Ahmed M.

doi:10.1016/j.jons.2017.01.001

Cited by 160 publications

(132 citation statements)

References 61 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…It is known that ER plays a role in cellular growth, proliferation, and differentiation. Both ER and PR are tumor markers that can effectively predict the hormonal responsiveness . HER‐2 has been proposed to estimate prognosis and guide treatment.…”

Section: Discussionmentioning

confidence: 99%

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Lian

Zhang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe utility of frequently used serum tumor markers in breast cancer remains controversial. The study aimed to investigate the role of preoperative carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 724 (CA724), and ferritin (FER) in the management of breast cancer and their relationships with pathological features.MethodsA total of 804 patients with breast mass who underwent breast surgery and 305 healthy volunteers were enrolled. Preoperative serum levels of CEA, CA125, CA153, CA724, and FER were measured. And the pathological features of all the patients were recorded. The association of preoperative serum tumor markers and pathological features was analyzed.ResultsAmong the 804 patients, 355 were identified as malignant cases and 449 as benign cases. CEA, CA153, and FER of patients with breast cancer were higher than those of healthy volunteer group and patients with benign breast diseases. The area under curve (AUC) of CEA, CA153, and FER for distinguishing patients with breast cancer and subjects with non‐breast cancer was 0.688 (95% CI: 0.656‐0.721), 0.609 (95% CI: 0.574‐0.645), and 0.623 (95% CI: 0.586‐0.660), respectively. CA153 correlated with tumor size, node status, and TNM stage, whereas CA125 with node status. No statistic differences of the five markers were observed among the four molecular subtypes.ConclusionPreoperative levels of CEA, CA153, and FER exhibit low diagnostic accuracy for breast cancer (stage I‐III). CA153 correlates with tumor burden, suggesting its prognostic value. The five serum markers do not correlate with molecular subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Lian

Zhang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Their detection and correlation with OSCC have been suggested to be potentially useful for clinical diagnosis and prognostic monitoring. Tumorderived markers are genes or proteins that play a direct role in carcinogenesis, and may sometimes also be used as biomarkers to improve cancer detection, predict disease outcome or response to therapy (20,21).…”

Section: Discussionmentioning

confidence: 99%

Expression of Tlr7 in Oral Squamous Cell Carcinoma and Its Correlation With Lymph Node Metastasis (An Immuno-Histochemical Study)

Youssef

Raslan

El‐Sheikh

et al. 2020

Alexandria Dental Journal

View full text Add to dashboard Cite

INTRODUCTION: Oral squamous cell carcinoma (OSCC) accounts for most of oral cancers which is about (90%) of all types. OSCC is an important cause of morbidity and mortality worldwide. Early detection; diagnosis and early treatment are still the key points for OSCC patients to improve survival rate and quality of life. Toll like receptors (TLRs), through their role in innate immunity, have been implicated in the pathogenesis of several diseases, including cancer and OSCC is one of these cancers. Nodal metastasis is playing a key role in detecting the prognosis and the outcome. TLR7 is one of the TLRS which is expressed in OSCC, the correlation between the expression of this receptor and the presence of nodal metastasis has been assessed and evaluated as TLR7 may be of great significance in tumors metastasis so can help in prognosis and aid in treatment modalities. OBJECTIVES: The aim of the present study was to evaluate the expression of TLR7 in the specimens of primary tumor tissues of OSCC and correlate it with the lymph node involvement. MATERIALS AND METHODS: TLR7expression was studied in 50 OSCC cases. The specimens were taken from the primary tumor of 25 cases with positively involved lymph nodes and another 25 cases with negatively involved lymph nodes and 10 normal mucosal tissues taken from OSCC patients and healthy individuals. Immuno-histochemical (IHC) staining was performed using the Labeled Strept-Avidin Biotin complex method (LSAB), using the anti-TLR7 antibody. RESULTS: TLR7 showed high expression in OSCC cases with positive lymph node metastasis than those with negative lymph node metastasis. CONCLUSIONS: TLR7 expression could be a guiding tool used to detect prognosis in OSCC patients and as an indicator for metastasis.

show abstract

“…He identified this glycoprotein whilst exploiting identical monoclonal antibody-mAb [121]. Serum levels of CA125 are clinically utilized to diagnose OC patients on basis of regression or progression of the disease, subsequent to standard chemotherapy [122]. Moreover, abnormal mucin expression can trigger immunity and probably cause a strong antibody response.…”

Section: Mucins As Targets For Antibodies In Chemotherapeuticsmentioning

confidence: 99%

“…The antibody response is symptomatic of disease expression [123]. Immunoglobulin Ig (antibodies) affiliated with mucins, can have potential application in the progression towards the detection and therapy of ovarian cancer; however, there are still few studies conducted to date [121][122][123].…”

Section: Mucins As Targets For Antibodies In Chemotherapeuticsmentioning

confidence: 99%

Nanodrug Delivery Systems for the Treatment of Ovarian Cancer

Pantshwa

Kondiah

Choonara

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe, early detection and active treatment of OC remains a challenge, in spite of improvements in new antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent and strategic approach has focused on nanosystem functionalization with antibody-based ligands to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting, whilst leaving normal cells unaffected. This article comprehensively reviews the present status of nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC. In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies to upsurge the survival rate of patients with OC.

show abstract

Tumor markers of breast cancer: New prospectives

Cited by 160 publications

References 61 publications

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Expression of Tlr7 in Oral Squamous Cell Carcinoma and Its Correlation With Lymph Node Metastasis (An Immuno-Histochemical Study)

Nanodrug Delivery Systems for the Treatment of Ovarian Cancer

Contact Info

Product

Resources

About